Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(50%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_3
1
17%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(3)

Detailed Status

Completed3
Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting233%
recruiting117%
completed350%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_3

A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

NCT07159763
active_not_recruitingphase_1

A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine

NCT07300085
active_not_recruitingphase_2

A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388

NCT07225959
completedphase_2

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

NCT06609460
completedphase_1

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

NCT05285137
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07159763Phase 3

A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

Recruiting
NCT07300085Phase 1

A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine

Active Not Recruiting
NCT07225959Phase 2

A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388

Active Not Recruiting
NCT06609460Phase 2

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

Completed
NCT05285137Phase 1

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Completed
NCT05619536Phase 1

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
6